ciprofloxacin.md

Ciprofloxacin

Seforce inj 400mg/200mL

TAH Drug Code	ISEF
Indications	Acute exacerbation of chronic bronchitis. Bacterial prostatitis, chronic. Bacterial sinusitis, acute. Febrile neutropenia, Empiric therapy. Gonorrhea, Uncomplicated. Infection of bone - Infectious disorder of joint. Infection of skin and/or subcutaneous tissue. Infectious diarrheal disease. Infectious disease of the abdomen, Complicated. Lower respiratory tract infection. Otitis externa, acute. Pyelonephritis. Urinary tract infectious disease.
Dosing	Should be infused intravenously over 60 minutes. Adults: usual dose: 100-400 mg IV Q12H; severe/complicated infections: 400 mg IV Q8H. Chiledren (aged 1-17 years): 6-10 mg/kg IV Q8-12H (maximum 400 mg/dose).
Hepatic Impairment	Dose adjustment not necessary
Renal Impairment	Dose adjustment required
Contraindications	Concomitant tizanidine administration. Hypersensitivity to ciprofloxacin or any product component, or other quinolones.
Adverse Effects	Common Dermatologic: Rash (Up to 1.8% ) Gastrointestinal: Diarrhea (Multiple indications, 1.6% to 4.8% ; Complicated UTI, 25% ), Nausea (Multiple indications, 2.5% to 4%; Complicated UTI 25% ), Vomiting (Adult, 1% to 2%; pediatric, 4.8% ) Neurologic: Headache (Up to 3% ) Psychiatric: Irritability (5% ) Respiratory: Nasal discharge (3% ), Nasopharyngitis (5% ) Serious Cardiovascular: Aortic aneurysm, Or dissection, Cardiorespiratory arrest (Up to 1% ), Myocardial infarction (Up to 1% ), Prolonged QT interval, Syncope (Up to 1% ), Torsades de pointes Dermatologic: Photosensitivity, Stevens-Johnson syndrome, Toxic epidermal necrolysis (Up to 1% ) Endocrine metabolic: Hypoglycemia (Up to 1% ) Gastrointestinal: Clostridium difficile colitis, Clostridium difficile diarrhea (Up to 1% ), Gastrointestinal hemorrhage (Up to 1% ), Pancreatitis (Up to 1% ) Hematologic: Agranulocytosis (Rare ), Aplastic anemia (Rare ), Bone marrow depression, Hemolytic anemia (Rare ), Leukopenia (0.4% ), Pancytopenia (0.1% ), Thrombocytopenia (Rare ) Hepatic: Hepatic necrosis (Up to 1% ), Hepatitis (up to 1% ), Hepatotoxicity, Liver failure Immunologic: Hypersensitivity reaction (Up to 1% ) Musculoskeletal: Myasthenia gravis, Exacerbation, Rupture of tendon, Tendinitis Neurologic: Disorientated, Disturbance of attention, Guillain-Barre syndrome, Memory impairment, Peripheral neuropathy, Pseudotumor cerebri, Raised intracranial pressure, Seizure (Less than 1% ) Ophthalmic: Retinal detachment Psychiatric: Delirium, Depression (Up to 1% ), Hallucinations, Paranoid disorder (Up to 1% ), Psychotic disorder (Up to 1% ), Suicidal behavior (Rare ) Renal: Acute renal failure (Up to 1% ), Hemorrhagic cystitis (Up to 1% ), Tubulointerstitial nephritis (Up to 1% )
Pregnancy	Contraindicated
Lactation	No (Limited) Human Data - Potential Toxicity
More Info	UpToDate

Cinolone F.C. 250mg

TAH Drug Code	OCINO
Indications	UTI .Respiratory tract, bone and joint and biliary tract infection.GI (infectious diarrhea). Gonorrhea.
Dosing	Take with or without food; do not take with milk, yogurt, or calcium-fortified juice; but may be taken with meals that contain these products. Adults: 250-750 mg orally Q12H. Children (1-17 years of age): 10-20 mg/kg Q12H (maximum. 750 mg/dose); inhalational anthrax (post-exposure): 15 mg/kg orally Q12H for 60 days (maximum. 500 mg/dose).
Hepatic Impairment	Dose adjustment not necessary
Renal Impairment	Dose adjustment required
Contraindications	Hypersensitivity to ciprofloxacin or other quinolones. Children, adolescents, pregnancy and lactation.
Adverse Effects	Nausea, diarrhoea, vomiting, dyspepsia, abdominal pain, flatulence, anorexia, dizziness, headache, tiredness, agitation, trembling. Very rarely, insomnia, peripheral paralgesia, sweating, unsteady gait, convulsions, increase in intracranial pressure, anxiety states, nightmares, confusion, depression, hallucinations, impaired taste & smell, visual disturbances, tinnitus, transitory impairment of hearing, especially at high frequencies, skin reactions.
Pregnancy	Contraindicated
Lactation	No (Limited) Human Data - Potential Toxicity
More Info	UpToDate